Biotech companies create drugs from living organisms, requiring a BLA for FDA approval. Pharma companies develop drugs from chemicals, needing an NDA for FDA approval. Many firms blend biotech and ...

No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception. This is because biology is by far the most “messy” of hard sciences. Chemistry or physics can deal ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

The downsizing is planned for May 12. — Cargo Therapeutics, 84 layoffs in San Carlos. The biotech company is halting development and is closing its San Carlos site. The downsizing is planned for ...

Alcon's acquisition of Aurion Biotech enhances its cell therapy capabilities for eye diseases, with Aurion operating independently under Alcon's support. Aurion's AURN001, an allogeneic cell therapy ...

Artificial intelligence (AI) has taken the biotech industry by storm, allowing companies to speed up the drug discovery process while also making it more cost-effective. With so many companies in the ...

CINCINNATI (Cincinnati Business Courier) - A growing biotech and pharmaceuticals manufacturer that announced a large investment in Greater Cincinnati a little over a year ago has unveiled new ...

Earlier this week, Novo Nordisk NVO signed an exclusive license agreement with China-based United Biotechnology for an experimental obesity drug in a deal valued at up to $2 billion. Through this ...

The biotech industry may be cooling off, but there’s still plenty to be excited about when it comes to the underlying innovations. Chances are, the next great medical breakthrough is already in ...

It has an all-new form factor, opening sideways rather than vertically. Huawei dresses the smartphone with a bunch of cool wallpapers. Here you can download Huawei Pura X wallpapers in high quality.

In exchange for its investment, Novo will gain exclusive worldwide rights to develop, manufacture and commercialize UBT251, the biotech’s investigational triple agonist of the GLP-1, GIP and glucagon ...

Cell programming biotech bit.bio is slimming its workforce by 25% as the company pivots to focus on biomedical tools instead of therapeutics development. The decision was driven by “shifting ...